Annexon Biosciences to Participate in Upcoming September Investor Conferences

Company Overview - Annexon, Inc. is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [1][2] - The company targets C1q, a key molecule in the classical complement pathway, to prevent tissue damage and inflammation in various diseases [2] Clinical Development - Annexon is advancing a late-stage clinical platform with investigational drug candidates aimed at addressing unmet medical needs for nearly 10 million people globally [2] - The therapeutic pipeline spans three areas: autoimmunity, neurodegeneration, and ophthalmology [2] Investor Engagement - Douglas Love, the president and CEO, will participate in investor conferences in September, including the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference [1][3] - Live webcasts of these presentations will be available on the company's website, with replays archived for 30 days [1]